HC Wainwright Lowers Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target to $50.00

Ultragenyx Pharmaceutical (NASDAQ:RARE) had its price target dropped by stock analysts at HC Wainwright from $60.00 to $50.00 in a research note issued to investors on Tuesday,Benzinga reports. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. HC Wainwright’s price target suggests a potential upside of 144.50% from the company’s current price.

Several other research analysts also recently weighed in on the stock. Guggenheim reduced their price target on shares of Ultragenyx Pharmaceutical from $64.00 to $52.00 and set a “buy” rating for the company in a research report on Monday, January 5th. Leerink Partners cut their price objective on Ultragenyx Pharmaceutical from $80.00 to $70.00 and set an “outperform” rating for the company in a research note on Tuesday, December 30th. Robert W. Baird decreased their target price on Ultragenyx Pharmaceutical from $72.00 to $47.00 and set an “outperform” rating on the stock in a research report on Tuesday, December 30th. Wells Fargo & Company lowered their price target on Ultragenyx Pharmaceutical from $65.00 to $45.00 and set an “overweight” rating on the stock in a research note on Tuesday, December 30th. Finally, TD Cowen dropped their price target on Ultragenyx Pharmaceutical from $86.00 to $75.00 and set a “buy” rating for the company in a research report on Wednesday, November 5th. Sixteen equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Ultragenyx Pharmaceutical currently has a consensus rating of “Moderate Buy” and an average price target of $68.29.

Ultragenyx Pharmaceutical Price Performance

Shares of RARE stock opened at $20.45 on Tuesday. Ultragenyx Pharmaceutical has a 1-year low of $18.41 and a 1-year high of $45.00. The company has a market cap of $1.97 billion, a price-to-earnings ratio of -3.50 and a beta of 0.16. The stock has a 50 day simple moving average of $25.96 and a 200-day simple moving average of $29.60.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its quarterly earnings results on Thursday, February 12th. The biopharmaceutical company reported ($1.29) EPS for the quarter, missing the consensus estimate of ($1.20) by ($0.09). The company had revenue of $207.28 million during the quarter, compared to analysts’ expectations of $199.60 million. Ultragenyx Pharmaceutical had a negative return on equity of 566.58% and a negative net margin of 85.54%.Ultragenyx Pharmaceutical’s revenue was up 25.5% compared to the same quarter last year. During the same period in the previous year, the firm posted ($1.39) EPS. Analysts anticipate that Ultragenyx Pharmaceutical will post -5.18 earnings per share for the current fiscal year.

Insider Transactions at Ultragenyx Pharmaceutical

In other news, CFO Howard Horn sold 3,061 shares of Ultragenyx Pharmaceutical stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $23.56, for a total transaction of $72,117.16. Following the transaction, the chief financial officer owned 88,935 shares in the company, valued at $2,095,308.60. The trade was a 3.33% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In the last three months, insiders sold 6,227 shares of company stock valued at $187,126. 5.50% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Ultragenyx Pharmaceutical

A number of institutional investors have recently bought and sold shares of the company. Vanguard Group Inc. increased its holdings in shares of Ultragenyx Pharmaceutical by 1.3% during the 4th quarter. Vanguard Group Inc. now owns 10,263,815 shares of the biopharmaceutical company’s stock worth $236,068,000 after buying an additional 131,087 shares during the last quarter. State Street Corp lifted its holdings in Ultragenyx Pharmaceutical by 16.5% in the fourth quarter. State Street Corp now owns 4,303,046 shares of the biopharmaceutical company’s stock valued at $98,970,000 after acquiring an additional 610,559 shares during the last quarter. Wellington Management Group LLP grew its position in Ultragenyx Pharmaceutical by 26.6% in the fourth quarter. Wellington Management Group LLP now owns 2,461,910 shares of the biopharmaceutical company’s stock worth $56,624,000 after acquiring an additional 516,781 shares during the period. Jacobs Levy Equity Management Inc. grew its position in Ultragenyx Pharmaceutical by 614.1% in the third quarter. Jacobs Levy Equity Management Inc. now owns 2,167,729 shares of the biopharmaceutical company’s stock worth $65,205,000 after acquiring an additional 1,864,164 shares during the period. Finally, Geode Capital Management LLC increased its stake in Ultragenyx Pharmaceutical by 16.3% during the fourth quarter. Geode Capital Management LLC now owns 1,838,208 shares of the biopharmaceutical company’s stock worth $42,287,000 after acquiring an additional 257,701 shares during the last quarter. 97.67% of the stock is owned by hedge funds and other institutional investors.

Trending Headlines about Ultragenyx Pharmaceutical

Here are the key news stories impacting Ultragenyx Pharmaceutical this week:

• Positive Sentiment: Canaccord lowered its price target to $79 from $128 but maintained a “buy” rating, citing continued upside potential (the new PT implies large upside versus current levels). Canaccord PT Cut
• Positive Sentiment: HC Wainwright cut its target to $50 (from $60) while keeping a “buy” rating, signaling broker confidence in longer‑term value despite lowering near‑term expectations. HC Wainwright Coverage
• Neutral Sentiment: Wedbush reaffirmed a “neutral” rating with a $25 price target, reflecting a more cautious near‑term view and limited upside relative to the current price. Wedbush Note
• Negative Sentiment: Multiple plaintiff law firms (Rosen, Levi & Korsinsky, Robbins LLP, Berger Montague, Bronstein Gewirtz & Grossman, Bragar Eagel & Squire, The Gross Law Firm, Kahn Swick & Foti, Schall Law Firm and others) have filed or are soliciting investors to join a securities‑class action covering purchases from Aug 3, 2023 to Dec 26, 2025 and are urging appointment of a lead plaintiff by April 6, 2026 — this creates legal and financial uncertainty (potential discovery, defense costs, settlement risk). Representative notices: Gross Law Firm Notice Levi & Korsinsky Notice Rosen Law Firm Notice

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.